Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

PURPOSE: Although several trials have demonstrated improved progression-free survival (PFS) with first-line regimens for HER2-negative metastatic breast cancer (mBC), overall survival (OS) benefit is elusive. We calculated required sample sizes to power for OS using published data from recent mBC tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kümmel, Sherko, Jackisch, Christian, Müller, Volkmar, Schneeweiss, Andreas, Klawitter, Sandra, Lux, Michael P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235000/
https://www.ncbi.nlm.nih.gov/pubmed/30519090
http://dx.doi.org/10.2147/CMAR.S177240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235000/
https://www.ncbi.nlm.nih.gov/pubmed/30519090
http://dx.doi.org/10.2147/CMAR.S177240

Ejemplares similares